First, studies performed on crizotinib upon its discovery showed that a high concentration of crizotinib (defined as >300 nM) displayed off-target effects [92]; and the IC50 for U937, a histiocytic lymphoma cell line used as a negative control (as it expresses neither ALK nor c-Met) was 257 nM [93]. The gene discussed is MET; the disease is reticulum cell sarcoma.